Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
Press releases published on August 25, 2025
Avalyn to Participate in Multiple Upcoming Investor Conferences in September
GlobeNewswire
·
August 25, 2025
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that management …
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
GlobeNewswire
·
August 25, 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved …
Fate Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
August 25, 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular …
4DMT to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 25, 2025
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …
Bright Minds Biosciences to Present at Upcoming Conferences
GlobeNewswire
·
August 25, 2025
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, …
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
GlobeNewswire
·
August 25, 2025
First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a …
Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line
GlobeNewswire
·
August 25, 2025
Fort Mill, S.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has …
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
GlobeNewswire
·
August 25, 2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new …
Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4
GlobeNewswire
·
August 25, 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration (FDA) has …
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
GlobeNewswire
·
August 25, 2025
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior …
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
GlobeNewswire
·
August 25, 2025
NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Ardelyx to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 25, 2025
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025
GlobeNewswire
·
August 25, 2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the …
Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 25, 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on …
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
GlobeNewswire
·
August 25, 2025
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical- …
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 25, 2025
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of …
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
GlobeNewswire
·
August 25, 2025
Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., …
OneMedNet Expands Multiple Revenue-Delivering Projects Under Evergreen Agreement With Top Medical Device Leader
GlobeNewswire
·
August 25, 2025
MINNEAPOLIS, Aug. 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announces significant adoption by one of the world’s top five medical device …
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
GlobeNewswire
·
August 25, 2025
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per …
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
GlobeNewswire
·
August 25, 2025
US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy …